The human acetylation genotype was determined by measuring urinary caffeine metabolites by use of a modification of a previously published HPLC method. The problem of separation of 7-methylxanthine (7X) from 1-methyluric acid (1U) in urine extracts was achieved by adding a phenyl column, in tandem with a C18 reverse-phase column, by means of a methanol: aqueous acetic acid gradient elution system. The urinary molar ratios of (AANIU)/ (AAA/1U + 1U + 1X) and (AAA/1U) / (1X) were estimated in 20 subjects phenotyped with dapsone, with 100% concordance for the [AAA/UNIX] ratio. A population study of 42 unrelated individuals exhibited trimodal distribution in acetylation capacity, consistent with the Hardy-Weinberg theory of population genetics. Defmitive pedigree analysis of 16 families (75 subjects) resulted in significant similarity between the observed genotypic matings and those expected by classical Mendelian segregation. This noninvasive genotyping method promises to be useful in future investigation of the relationship between the human acetylation polymorphism and clinical disorders. (CLIN PHARMACOL THER 1990;47:470-7.) Anthony J. Kilbane, MB, BCh,a Lawrence K. Silbart, PhD,b Melanie Manis, PhD,c mese Z. Beitins, MD,d and Wendell W. Weber, MD, Phi) Ann Arbor, Mich.
circumvent some of the problems mentioned above, inasmuch as this universally available substance is consumed on a daily basis by a substantial number of people.
The isolation' and identification by HPLC" of a urinary caffeine metabolite, 5-acetylamino-6-amino-3-methyluracil (AAMU), and an additional unidentified acetylated metabolite, excreted in urine in varying concentrations depending on the acetylator phenotype,14 led to further evaluation of caffeine as a suitable substrate for investigation of the human acetylation polymorphism. This latter compound, identified as 5-acetylamino-6-formylamino-3-methyluracil (AFMU), was proved to be a major uracilic metabolite of caffeine.1516 Urinary concentration of AFMU was directly related to N-acetyltransferase enzyme activity'' and formed the basis for determination of the acetylator phenotype by use of the urinary molar ratio of AFMU to 1-methylxanthine (1X).18 Instability of AFMU and its spontaneous conversion to AAMU by deformylation with dilute sodium hydroxide led to quantitation of the urinary molar ratio of (AAMU)/ (1X) to determine the acetylator phenotype. 19 AAMU was found to be more stable than its biologic precursor. In an attempt to separate homozygous from heterozygous rapid acetylators, the urinary molar ratio of (AAMU)/ (AAMU + 1U + IX) was measured in a selected population and reflected a trimodal distribution in N-acetylation patterns. ' The purpose of the present study is, through studies of a random population combined with family pedigree analysis, to further investigate the urinary molar ratio of AAMU to products (1U and 1X) of the 7-demethylation pathway of paraxanthine (1,7-dimethylxanthine) metabolism, for future application as an acetylator genotyping method.
METHODS
Subjects. After receiving approval from the Human Resources Committee of the University of Michigan (Ann Arbor, Mich.), subjects in the study were requested to avoid food and beverages that contained methylxanthines for 48 hours or longer. Subjects then consumed a caffeine-containing drink, (e.g., coffee or cola) and supplied a urine sample 6 hours later. After adjustment of each urine sample to pH 3.5 with 6N hydrochloride, a 10 ml aliquot was stored at 20° C until assayed. Excluded from the study were individuals with idiosyncratic reactions (e.g., tachycardia, tremors, and insomnia) to caffeine. No other specific dietary restrictions were enforced. Three groups of individuals were then analyzed as follows: (1) Twenty healthy subjects, previously phenotyped with dapsone by use of the method of Can et al.,' were selected and retested by use of the caffeine method; (2) a population study of 42 unrelated adult white persons from the local community was undertaken to estimate the gene frequency and to further evaluate the expected trimodal distribution pattern; and (3) informative family studies of patients with type I (insulin-dependent) diabetes mellitus, attending the pediatric endocrinology clinics at the University of Michigan hospitals, and their first-degree relatives, in addition to families living in the locality, were tested for acetylation capacity. A detailed pedigree analysis, consisting of 16 families (75 subjects), was undertaken to assess the Mendelian segregation patterns.
Material. Caffeine, 1-methyluric acid (1U), 1-methylxanthine ( I X), N-acetyl-p-amidophenol , benzyloxyurea, and 7-methylxanthine (7X) were obtained from Sigma Chemical Co. (St. Louis, Mo.) at the highest purity available. AFMU was supplied by Dr. W. Kalow (University of Toronto, Toronto, Ontario, Canada). All HPLC buffers were spectroscopic grade.
AAMU was prepared by deformylation of AFMU with dilute sodium hydroxide.
Analytic procedures. Because of incomplete resolution of AFMU from interfering peaks in the early phase of the chromatogram with the C18 octyldecylsilane reverse-phase column, urinary AAMU concentration was measured by the HPLC method of Tang et al. ' The stored urine samples were thawed and a 50 p.1 aliquot was withdrawn and treated with 50 p.1 of 0.2N sodium hydroxide for 10 minutes at room temperature to achieve a final pH greater than 8, for quantitative deformylation of AFMU to AAMU. Then 50 pd of 0.2 mol/ L hydrochloride was added to neutralize excess base and 100 pi of the internal standard, benzyloxyurea
(1 mg/ ml in 0.1% aqueous acetic acid) was added, from which a 20 p.1 sample was injected onto a BioGel TSK-20 (300 x 7.5 mm) size exclusion HPLC column (Richmond, Calif.). A Varian 5060 programmable HPLC solvent delivery system (Walnut Creek, Calif.) with a Rheodyne injector (Cotati, Calif.), Varian ultraviolet-100 detector, and a Spectrophysics SP4270 integrator (San Jose, Calif.) were used to perform the separation and quantitation. An isocratic elution with 0.1% aqueous acetic acid at 0.8 ml per minute flow rate was maintained, and the column eluent ultraviolet absorption was monitored at 254 nm. The identical protocol was performed with baseline urine samples that were spiked with known amounts of AAMU standards. By use of a C/8 reverse-phase column under the HPLC conditions reported by Grant et al.," difficulties CLIN PHARMACOL THER APRIL 1990 in the separation of 1U from 7X were encountered in at least one third of the urine samples tested ( Fig. 1) , which persisted despite manipulation of the gradient conditions. For quantitation of 1U and 1X, a modification of the method of Grant et al." was used. To a 200 p.1 urine sample was added 120 mg ammonium sulfate, and the sample was then vortexed briefly in a 15 ml Corex (Corning, Corning, N.Y.) tube. A 200 p.1 aliquot of the internal standard, N-acetyl-p-amidophenol (100 mg/L in chloroform) was added, followed by the addition of 6 ml chloroform: isopropanol (85 :15) and the mixture was vortexed for 30 seconds. After centrifugation at 2,500g for 5 minutes at room temperature, the aqueous phase was removed and discarded, and the organic phase was evaporated to dryness with a gentle stream of nitrogen at 45°C. The residue was redissolved in 800 RI methanol/ 0.05% aqueous acetic acid-water (12:88, vol/vol). A 20 R.1 aliquot was then injected onto a Waters RBondapak phenyl column (3.9 x 150 mm; Waters Associates, Milford, Mass.) in tandem with a Beckman Ultrasphere octyldecylsilane column (5 p.m. 250 x 4.6 mm; Beckman Instruments, Palo Alto, Calif.) to separate 1U from 7X. Separation was consistently accomplished by use of the gradient elution profile shown in Fig. 2 . The addition of a phenyl column improved the resolution of these metabolites, allowing satisfactory quantitation of both 1U
and 7X on all samples tested. It was not unusual for the integrated 7X signal to exceed that of 1U, and attempts to separate these metabolites by use of a phenyl column alone were unsuccessful. The identical protocol was performed with baseline urine samples that were spiked with known amounts of 1X and 1U standards, and the ultraviolet absorbance was monitored at 272 nm. Standard curves relating the integrated signal values (relative to the internal standard, N-acetyl-pamidophenol) versus known amounts of 1X and 1U standards, processed as above, were constructed. Subsequent urinary IX and 1U concentrations were calculated by interpolation from the linear standard curve.
Phenotype determination. The acetylation phenotype of 20 individuals, previously tested with dapsone, was determined by use of the modified caffeine method. Subjects chosen were slow (eight), intermediate (eight), or rapid (four) metabolizers of dapsone. The dapsone method relies on determination of the ratio of N-acetyldapsone to dapsone in serum, 3 hours after oral administration of the parent drug.' A Nacetyldapsone/dapsone ratio of 0.26 separates slow from rapid acetylators. terday coefficients of variation were as follows: 6% to 12% for AAMU, 4% to 12% for 1X, and 5% to 11% for 1U.
The N-acetyldapsone/dapsone ratio is compared with the urinary molar ratio of (AAMU)/(AAMU + 1U + 1X) and (AAMU)/ (1X) (Fig. 3) . Arbitrary antimodes at 1.82 and 6.60 for the (AAMU)/ (1X) ratio, the urinary molar ratio of (AAMU)/ (1X), but the (AAMU)/(AAMU + 1U + 1X) ratio for two individuals (A and B) was distorted. A more comprehensive analysis of the trimodal acetylation patterns, observed by use of the modified caffeine method, was subseUrinary metabo ite concen rations (mol/L), (AAMU)/(AAMU + 1U + IX), and (AAMU)/(1X) molar ratios and family pedigrees. For acetylation genotype determination in the family pedigrees, the molar ratio of (AAMU)/(1X) was used.
AAMU, 5-Acetylamino-6-amino-3-methyuracil; 1U, 1-methyluric acid; IX, 1-methylxanthine. *Subjects A and B.
quently undertaken by testing 42 unrelated healthy subjects. The trimodal distribution patterns of acetylation in this group is demonstrated by the histogram (Fig.  4) , in which the observed values are consistent with those expected by application of the Hardy-Weinberg theory of population genetics.
Studies of informative families were also undertaken to further evaluate the potential genotyping capacity of this method. The urinary concentra- ratios and family pedigree analysis are outlined in Table   I . The observed genotypic matings and resulting offspring in 16 white families (75 individuals) are compared with those expected (Table II) . The x2 calculations reflect no significant difference between the observed values and those expected by classical Mendelian segregation.
DISCUSSION
When isonicotinic acid hydrazide (isoniazid) was first introduced as a tuberculostatic chemotherapeutic agent in the early 1950s,22 it soon became apparent that considerable interindividual variation in the urinary excretion rates of the parent compound and its acetylated metabolite existed. [23] [24] [25] This variation in isoniazid acetylation was later shown to be genetically determinee" and reflected varying activity of human liver N-acetyltransferase.3 Peripheral neuritis was observed in slow metabolizers of isoniazid,"'" and since then, several important associations between acetylator status and clinical disorders have been described. Drug toxicities of significance include the development of lupus erythematosus in slow metabolizers exposed to hydralazine" and procainamide."'" Slow acetylators exposed to sulfasalazine exhibit cutaneous discoloration' and hematologic abnormalities,' which are attributed to high levels of the sulfa metabolite, Nhydroxysulfapyridine."'" Statistical associations exist between slow acetylator phenotype and the development of bladder cancer."' A significant association also exists between the rapid acetylator phenotype and type I (insulin-dependent) diabetes mellitus in Europeans."'39 To further evaluate the potential implications of the acetylation polymorphism and its effect on human response to drugs, especially in well-documented clinical situations, a rapid, noninvasive, and easily reproducible genotyping method would be desirable. In elucidation of the efficacy of the modified caffeine genotyping method, several problems were encountered that warrant amplification. Because of instability of AFMU, notably at pH 5 or greater,' and its degradation over time," we proceeded to deformylate AFMU to the stable compound,' AAMU, knowing this conversion had, in all probability, partially occurred in urine present in the bladder under physiologic pH conditions.' Furthermore, because of incomplete resolution of AFMU by use of the single C,, reverse-phase column, we elected to phenotype individuals by use of the (AAMU)/(AAMU + 1U + 1X) ratio, as described by Tang et al.' It became apparent, however, that incomplete separations of 1U from 7X frequently occurred. This particular problem has been observed in other HPLC systems when attempting to separate 7-methylxanthine and 1-methyluric acid.' The addition of a phenyl column in advance of and in tandem with the C18 column resulted in satisfactory resolution of the 1U and 7X metabolites. The phenyl column was selected for the separation of these metabolites on the basis of previous success with this column for the separation of methylated purines." Two of our test subjects (A and B, Fig. 3 ) were receiving theophylline for bronchial asthma. Our observations suggested that, when testing subjects on theophylline, the acetylator genotype determination must be interpreted with caution when the (AAMU)/ (AAMU + 1U + 1X) ratio is used. High urinary 1-methyluric acid (and coincidental low 1-methylxanthine) levels in subjects taking theophylline have been described."'" An apparent slower acetylating capacity of these individuals is thus reflected by the (AAMU)/ (AAMU + 1U + 1X) molar ratio. Consequently, the alternative ratio of (AAMU)/ (IX), which showed excellent correlation with the Nacetyldapsone / dapsone ratio (Fig. 3) , could be used to good effect in this situation. The results of family pedigree analysis (Tables I and  II) Problems with AFMU instability, particularly when stored in the bladder, are avoided when deformylation to AAMU is undertaken.' Our data suggest that the ratio of (AAMU)/ (IX), based on family studies, reliably separates the three genotypes and is suggested as the ratio of choice for future investigation. It is also clear that, in this situation, measurement of urinary 1-methyluric acid is no longer warranted because it offers no additional assistance when identification of the genotypes is attempted. The addition of a phenyl column (used in this study for accurate quantitation of 1U) will, therefore, not be required when the urinary ratio of (AAMU)/ (1X) is used to determine the acetylator genotype. With each run for the size exclusion column taking 35 to 40 minutes, up to 12 individuals could be genotyped in a day.
Our study has reconfirmed the trimodal distribution patterns of acetylation in a population group with use of caffeine as a test drug, highlighted several problems in methods that were rectified, extended previous observations to include detailed family studies that demonstrate the expected Mendelian segregation patterns, and shown that the (AAMU)/ (1X) ratio is preferable to the (AAMU)/(AAMU + 1U + 1X) ratio in distinguishing heterozygous from homozygous rapid acetylators. The data also suggest the ratio (AAMU)/ (IX) can be used reliably when estimating acetylation capacity in patients taking theophylline, but this warrants further investigation.
